抗苯丙氨酸羟化酶单克隆抗体的提纯和轻、重链的N端顺序

利用DEAE-52离子交换层析和FPLC的Mono Q离子交换柱,从鼠的腹水液中提纯抗苯丙氨酸羟化酶单克隆抗体,再利用FPLC的Superose 12凝胶柱分离它们的轻链和重链。经SDS-凝胶电泳,氨基酸组成分析和N端顺序测定,确定轻链的分子量约为24 kD,约含有215个残基,轻链的N端的顺序是:D-V-V-M-T-Q-T-P-L-S-L-P-V-S-L-G-D-Q-A-S-I-S-C-R-S-D?-Q-N(D)-,并确认该轻链为鼠KaPPa轻链Ⅱ型。重链的分子量约为52 kD,它的末端被焦谷氨酰封闭。     

人心肌肌球蛋白轻链1与重链和肌动蛋白的结合

在测得中国人心肌肌球蛋白轻链 1cDNA的核苷酸序列 ,并获得一株单克隆抗体 (HCMLC1 8)的基础上 ,用PCR方法 ,以中国人心肌肌球蛋白轻链 1的cDNA为模板 ,分别获得中国人心肌肌球蛋白轻链 1的各为 98个氨基酸的N端和C端片段cDNA的克隆并进行了表达。同时进行了其表达产物和大鼠心肌肌球蛋白重链和人心肌肌动蛋白以及单克隆抗体结合的研究 ,发现三者均和轻链 1的N端相结合 ,结合位点各不相同。这些结合位点可能均位于轻链 1的分子表面 ,而且如果轻链 1在实验状态下先与肌动蛋白结合 ,则有可能影响轻链与重链间的彼此结合。肌动蛋白在体外能以不同位点结合肌球蛋白重链和轻链 ,可能在肌肉收缩过程中具有重要的生理意义     

重组人源性抗HBsAg Fab抗体纯化方法的比较研究

抗HBsAg Fab抗体被认为在预防和治疗HBV引起的肝病中具有重要的作用。为了建立稳定的、适于生产应用的重组人源性抗HBsAg Fab抗体的纯化工艺,本实验对不同纯化方法进行了比较研究。比较了抗Fab抗体亲和层析、ScFv单克隆抗体亲和层析和离子交换层析等3套纯化工艺在酵母发酵生产的重组人源性抗HBsAg Fab抗体纯化中的效率。结果显示,抗Fab抗体亲和层析柱纯化酵母表达的重组Fab,纯度为96．8％,但回收率偏低,只有30％～40％。ScFv单克隆抗体亲和层析纯化的重组Fab,纯度为97．5％,回收率达75％～85％。该工艺能很好的适应较小规模的生产应用。离子交换层析纯化的重组Fab,纯度为97％,回收率为75％～85％。该工艺能很好的适应较大规模的生产应用。以上结果表明,应用ScFv单克隆抗体亲和层析和离子交换层析纯化技术均能很好的纯化出重组人源性抗HBsAg Fab抗体,这两种纯化工艺不仅大大节约纯化成本,且纯化效率和回收率有很大提高。为莺组Fab抗体的工业化生产应用奠定了基础。     

人心肌肌球蛋白链1与重链和肌动蛋白的结合

在测得中国人心肌肌球蛋白轻链1cDNA的核苷酸序列,并获得一株单克隆抗体（HCMLC1－8）的基础上,用PCR方法,以中国人心肌肌球蛋白轻链1的cDNA模板,分别获得中国人心肌肌球蛋白轻链1的各为98个氨基酸的N端和C端片段cDNA的克隆并进行了表达。同时进行了其表达产物和大鼠心肌肌球蛋白重链和人心肌肌动蛋白以及单克隆抗体结合的研究,发现三者均和轻链1的N端相结合,结合们点各不相同。这些结合位点可能均位于轻链1的分子表面,而且如果轻链1在实验状态下先与肌动蛋白结合,则有可能影响轻链与重链间的彼此结合,肌动蛋白在体外能以不同位点结合肌球蛋白重链和轻链,可能在肌肉收缩过程中具有重要的生理意义。     

人源性抗HBsAg抗体Fab段在酵母中的表达

通过分步整合的方式,将人源性抗乙肝表面抗原（HBsAg）抗体Fab的轻、重链基因分步整合到巴斯德毕赤（Pichia pastoris）酵母GS115菌株的染色体上,经甲醇诱导,成功地分泌表达出抗HBsAg抗体的Fab片段,表达量达50～80mg/L。ELISA结果显示重组酵母分泌表达出的Fab具有较强的结合HBsAg的能力。通过抗Fab的抗体柱亲和层析,纯化出了纯度较高的Fab产品。     

抗肠炎沙门氏菌单链抗体制备及其特异性分析

目的:利用基因工程技术制备抗肠炎沙门氏菌的单链抗体.方法:从抗肠炎沙门氏菌单克隆抗体的杂交瘤细胞中纯化RNA,反转录后扩增出抗体的重链可变区(VH)和轻链可变区(VL)基因片段,采用重叠延伸的方法,用柔性多肽Linker接头(Gly4 Ser)3按VL-Linker-VH方式将VH基因和VL基因拼接成单链抗体基因片段后,连接到pGEX-4T-1载体上,进行重组转化.挑取阳性克隆,经IPTG诱导后,通过GST柱进行亲和层析,最后利用ELISA检测抗体的活性.结果:成功构建了表达抗肠炎沙门氏菌单链抗体的基因工程菌株,经SDS-PAGE和ELISA检测结果表明,诱导表达的单链抗体scFv分子量约为60 kDa,其能特异与肠炎沙门氏菌结合,但与副甲伤寒沙门氏菌、鸭沙门氏菌、鼠伤寒沙门氏菌有轻度交叉反应.结论:成功构建了抗肠炎沙门氏菌单链抗体的表达菌株,表达的单链抗体scFv可作为沙门氏菌的检测的候选抗体分子.     

基于重链抗体构建的单域抗体研究进展

在骆驼血清中存在天然的缺失轻链的重链抗体(heavy chainantibody ,HCAb) ,克隆重链抗体的可变区构建的只由一个重链可变区组成的单域抗体称为VHH抗体(variabledomainofheavychainofheavy chainantibody ,VHH)。研究发现,VHH抗体具有易表达、可溶性好、稳定性强等优点。另外,骆驼的重链抗体与人VH3家族抗体同源,对人VH3家族抗体的重链可变区进行类似VHH的特征性改造,可以使这些抗体在保持亲和力、特异性不变或者变化很小的情况下,优化抗体的其它性质。已有的研究表明VHH抗体作为一种小型化的基因工程抗体在基础研究、药物开发等领域有广阔的应用前景。     

利用单细胞RT-PCR体外克隆个体化乙型肝炎表面抗体重链

目的建立一种利用单细胞RT-PCR技术克隆乙型肝炎表面抗体重链的方法,为人源化、个体化的乙肝治疗性抗体研制奠定基础。方法利用单细胞分选技术从乙肝疫苗接种志愿者外周血中分选得到单个抗体分泌细胞（antibody-secreting cells,ASC）,用单细胞RT-PCR克隆其IgG重链全长到pEGFP-N1载体,转染COS-7细胞,上清液用乙肝表面抗原（hepatitis B surface antigen,HBsAg）通过Western blot进行结合力验证。结果克隆得到1 500 bp左右的重链全长,重链表达产物经验证能与乙肝表面抗原特异结合。结论克隆得到表达产物能与HBsAg特异结合的重链基因,为我们后期制备抗体轻链、连接轻重链和抗体亲和力鉴定奠定基础。     

抗VEGF单克隆抗体Fab片段在E.coli中的分泌表达

目的：在大肠杆菌中构建、表达和纯化抗血管内皮生长因子（VEGF）的Fab片段（兰尼单抗,ranibizumab）,通过发酵条件的控制实现其在大肠杆菌周质和胞外的高效分泌表达,并检测其抗VEGF的活性。方法：以pET30a为质粒载体,构建了Fd链和L链前都含有OmpA信号肽、SD序列和T7 promoter的克隆载体pET30a（+）-LC-HC,转化BL21（DE3）表达菌株,并进行了培养基、温度和IPTG诱导浓度的条件优化。结果：确定Fab片段在大肠杆菌分泌表达摇瓶发酵最佳条件为：在含有1.5% Tryptone,1% Yeast Extract,0.5% Glucose,0.15% NaCl,0.1% NH₄Cl,0.08% MgCl₂·6H₂O的1L培养基的摇瓶中,按照10%的接种量,37℃摇床培养至对数生长后期（OD₆₀₀为2左右）,添加0.1mmol/L IPTG诱导剂,于16℃条件下诱导表达过夜（16h左右）。用周质破菌提取分泌至大肠杆菌周质腔的Fab片段,同时用中空纤维柱浓缩发酵培养基,最后用ProteinG亲和层析柱一步纯化洗脱,经SDS-PAGE检测分析和Brandford法测蛋白浓度得出纯化的Fab抗体片段纯度在90%以上,分泌表达纯化量为0.4mg/L。以VEGF165作为结合抗原,间接ELISA分析纯化后的Fab抗体EC50=30ng/ml。继续用该培养基在3.7L体积发酵罐中进行2L体积的发酵,获得最终的菌体产率为30g/L,可亲和纯化Fab抗体量为1.94mg/L。结论：成功实现了Fab抗体片段在大肠杆菌中的高效分泌表达,且具有很高的活性,为规模化制备Fab抗体片段提供了研究依据。     

人源抗滋养层细胞表面抗原?鄄2基因工程抗体Fab的制备及特性分析

应用噬菌体抗体库技术制备全人源抗滋养层细胞表面抗原-2(Trop-2)特异性Fab抗体片段．抗体库经细胞筛选和固相抗原筛选,获得特异性的阳性克隆．阳性载体经核酸序列分析后,构建工程菌,经IPTG诱导表达,SDS-PAGE和Western blot分析,呈现28 ku和32 ku大小的两条蛋白质条带．Fab分子经流式细胞术、细胞免疫荧光检测,结果表明,Fab能够与BxPc3细胞膜蛋白特异性结合,而与NIH3T3细胞不结合．免疫共沉淀与质谱分析结果表明,该Fab分子能够与Trop-2蛋白特异性结合．免疫组化显示,该抗体可结合胰腺癌细胞膜蛋白,在细胞培养液中加入Fab,能够抑制BxPc3细胞的生长．以上研究结果提示,该抗体有望成为胰腺癌临床影像诊断或治疗的候选分子．     

Dissecting the Alternatively Folded State of the Antibody Fab Fragment

Intact antibodies and antigen binding fragments (Fab) have been previously shown to form an alternatively folded state (AFS) at low pH. This state consists primarily of secondary structure interactions, with reduced tertiary structure content. The AFS can be distinguished from the molten globule state by the formation of nonnative structure and, in particular, its high stability. In this study, the isolated domains of the MAK33 (murine monoclonal antibody of the subtype κ/IgG1) Fab fragment were investigated under conditions that have been reported to induce the AFS. Surprising differences in the ability of individual domains to form the AFS were observed, despite the similarities in their native structures. All Fab domains were able to adopt the AFS, but only for V_H (variable domain of the heavy chain) could a significant amount of tertiary structure be detected and different conditions were needed to induce the AFS. V_H, the least stable of the domains under physiological conditions, was the most stable in the AFS, yet all domains showed significant stability against thermal and chemical unfolding in their AFS. Formation of the AFS was found to generally proceed via the unfolded state, with similar rates for most of the domains. Taken together, our data reveal striking differences in the biophysical properties of the AFS of individual antibody domains that reflect the variation possible for domains of highly homologous native structures. Furthermore, they allow individual domain contributions to be dissected from specific oligomer effects in the AFS of the antibody Fab fragment.     

小鼠抗天花粉蛋白IgE型单抗的酶解及其Fab的制备

研究了Ｐａｐａｉｎ及Ｔｒｙｐｓｉｎ裂解小鼠抗天花粉蛋白ＩｇＥ单抗的条件及Ｆａｂ的制备。Ｐａｐａｉｎ和Ｔｒｙｐｓｉｎ两者都可产生Ｆ（ａｂ′）_２,分子量在１５０～１６０ｋＤ左右;经Ｐａｐａｉｎ裂解的主要产物中还有Ｆａｂ,分子量７２ｋＤ,可通过凝胶过滤获得纯的Ｆａｂ。而Ｔｒｙｐｓｉｎ裂解物经ＤＴＴ还原、碘乙酰胺烷化虽然也可得到Ｆａｂ′（ｔ）,但不易纯化;可见,要制备Ｆａｂ以采用Ｐａｐａｉｎ裂解为好,而制备Ｆ（ａｂ′）_２则可采用Ｔｒｙｐｓｉｎ裂解。这二个酶的裂解速度是Ｔｒｙｐｓｉｎ大于Ｐａｐａｉｎ。     

抗乙肝病毒表面抗原嵌合抗体基因在昆虫细胞中的表达

应用杆状病毒表达系统在昆虫细胞中表达了抗乙肝病毒表面抗原（ＨＢｓＡｇ）人－鼠嵌合抗体重,轻链基因,鼠源单克隆抗体ＯＨ３重,轻链可变区（ＶＨ,ＶＬ）ｃＤＮＡ分别与人免疫球蛋白恒区γ３,ｋ,ｃＤＮＡ拼接成人－鼠嵌合抗体基因,含嵌合抗体的转移载体与线性化病毒ＤＮＡ共转染Ｓｆ９细胞,并通过点杂交ＰＣＲ扩增和Ｓｏｕｔｈｅｒｎｂｌｏｔ分析获得重组病毒。Ｗｅｓｔｅｒｎｂｌｏｔ和竞争ＥＬＩＳＡ表明以重组病毒感染的     

Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans

Amyloid light chain (AL) amyloidosis is a protein misfolding disease where immunoglobulin light chains sample partially folded states that lead to misfolding and amyloid formation, resulting in organ dysfunction and death. In vivo, amyloid deposits are found in the extracellular space and involve a variety of accessory molecules, such as glycosaminoglycans, one of the main components of the extracellular matrix. Glycosaminoglycans are a group of negatively charged heteropolysaccharides composed of repeating disaccharide units. In this study, we investigated the effect of glycosaminoglycans on the kinetics of amyloid fibril formation of three AL cardiac amyloidosis light chains. These proteins have similar thermodynamic stability but exhibit different kinetics of fibril formation. We also studied single restorative and reciprocal mutants and wild type germ line control protein. We found that the type of glycosaminoglycan has a different effect on the kinetics of fibril formation, and this effect seems to be associated with the natural propensity of each AL protein to form fibrils. Heparan sulfate accelerated AL-12, AL-09, κI Y87H, and AL-103 H92D fibril formation; delayed fibril formation for AL-103; and did not promote any fibril formation for AL-12 R65S, AL-103 delP95aIns, or κI O18/O8. Chondroitin sulfate A, on the other hand, showed a strong fibril formation inhibition for all proteins. We propose that heparan sulfate facilitates the formation of transient amyloidogenic conformations of AL light chains, thereby promoting amyloid formation, whereas chondroitin sulfate A kinetically traps partially unfolded intermediates, and further fibril elongation into fibrils is inhibited, resulting in formation/accumulation of oligomeric/protofibrillar aggregates.     

Biochemical Features of a Catalytic Antibody Light Chain, 22F6, Prepared from Human Lymphocytes

Human antibody light chains belonging to subgroup II of germ line genes were amplified by a seminested PCR technique using B-lymphocytes taken from a human adult infected with influenza virus. Each gene of the human light chains was transferred into the Escherichia coli system. The recovered light chain was highly purified using a two-step purification system. Light chain 22F6 showed interesting catalytic features. The light chain cleaved a peptide bond of synthetic peptidyl-4-methyl-coumaryl-7-amide (MCA) substrates, such as QAR-MCA and EAR-MCA, indicating amidase activity. It also hydrolyzed a phosphodiester bond of both DNA and RNA. From the analysis of amino acid sequences and molecular modeling, the 22F6 light chain possesses two kinds of active sites as amidase and nuclease in close distances. The 22F6 catalytic light chain could suppress the infection of influenza virus type A (H1N1) of Madin-Darby canine kidney cells in an in vitro assay. In addition, the catalytic light chain clearly inhibited the infection of the influenza virus of BALB/c mice via nasal administration in an in vivo assay. In the experiment, the titer in the serum of the mice coinfected with the 22F6 light chain and H1N1 virus became considerably lowered compared with that of 22F6-non-coinfected mice. Note that the catalytic light chain was prepared from human peripheral lymphocyte and plays an important role in preventing infection by influenza virus. Considering the fact that the human light chain did not show any acute toxicity for mice, our procedure developed in this study must be unique and noteworthy for developing new drugs.     

The Plasmodium Class XIV Myosin,MyoB, Has a Distinct Subcellular Location in Invasive and Motile Stages of the Malaria Parasite and an Unusual Light Chain

Myosin B (MyoB) is one of the two short class XIV myosins encoded in the Plasmodium genome. Class XIV myosins are characterized by a catalytic “head,” a modified “neck,” and the absence of a “tail” region. Myosin A (MyoA), the other class XIV myosin in Plasmodium, has been established as a component of the glideosome complex important in motility and cell invasion, but MyoB is not well characterized. We analyzed the properties of MyoB using three parasite species as follows: Plasmodium falciparum, Plasmodium berghei, and Plasmodium knowlesi. MyoB is expressed in all invasive stages (merozoites, ookinetes, and sporozoites) of the life cycle, and the protein is found in a discrete apical location in these polarized cells. In P. falciparum, MyoB is synthesized very late in schizogony/merogony, and its location in merozoites is distinct from, and anterior to, that of a range of known proteins present in the rhoptries, rhoptry neck or micronemes. Unlike MyoA, MyoB is not associated with glideosome complex proteins, including the MyoA light chain, myosin A tail domain-interacting protein (MTIP). A unique MyoB light chain (MLC-B) was identified that contains a calmodulin-like domain at the C terminus and an extended N-terminal region. MLC-B localizes to the same extreme apical pole in the cell as MyoB, and the two proteins form a complex. We propose that MLC-B is a MyoB-specific light chain, and for the short class XIV myosins that lack a tail region, the atypical myosin light chains may fulfill that role.